162 related articles for article (PubMed ID: 37478970)
1. On the Risk of Nitrosamine Contamination During Drug Product Blister Packaging.
Zheng J; Brookes A; Moser J; Pfeffer H; Smith A
J Pharm Sci; 2023 Sep; 112(9):2321-2325. PubMed ID: 37478970
[TBL] [Abstract][Full Text] [Related]
2. Nitrocellulose blister material as a source of N-nitrosamine contamination of pharmaceutical drug products.
Golob N; Grahek R; Ross M; Roškar R
Int J Pharm; 2022 Apr; 618():121687. PubMed ID: 35314277
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a Novel LC-MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials.
Kartop RA; Güleli M; Faruzlu FA; Çalışkan C
J Pharm Sci; 2024 Jun; 113(6):1597-1606. PubMed ID: 38253223
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous determination of low molecular weight nitrosamines in pharmaceutical products by fast gas chromatography mass spectrometry.
Kalauz A; Tiringer KV; Horváth V; Kapui I
J Chromatogr A; 2023 Oct; 1708():464323. PubMed ID: 37696123
[TBL] [Abstract][Full Text] [Related]
5. Estimated Cancer Risks Associated with Nitrosamine Contamination in Commonly Used Medications.
Li K; Ricker K; Tsai FC; Hsieh CJ; Osborne G; Sun M; Marder ME; Elmore S; Schmitz R; Sandy MS
Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574388
[TBL] [Abstract][Full Text] [Related]
6. Presence of nitrosamine impurities in medicinal products.
Sedlo I; Kolonić T; Tomić S
Arh Hig Rada Toksikol; 2021 Mar; 72(1):1-5. PubMed ID: 33787187
[TBL] [Abstract][Full Text] [Related]
7. A Full Evaporation Static Headspace Gas Chromatography Method with Nitrogen Phosphorous Detection for Ultrasensitive Analysis of Semi-volatile Nitrosamines in Pharmaceutical Products.
Zheng J; Kirkpatrick CL; Lee D; Han X; Martinez AI; Gallagher K; Evans RK; Mudur SV; Liang X; Drake J; Buhler LA; Mowery MD
AAPS J; 2022 Jan; 24(1):23. PubMed ID: 34993666
[TBL] [Abstract][Full Text] [Related]
8. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
Bharate SS
J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
[TBL] [Abstract][Full Text] [Related]
9. The contamination of valsartan and other sartans, part 1: New findings.
Sörgel F; Kinzig M; Abdel-Tawab M; Bidmon C; Schreiber A; Ermel S; Wohlfart J; Besa A; Scherf-Clavel O; Holzgrabe U
J Pharm Biomed Anal; 2019 Aug; 172():395-405. PubMed ID: 31122801
[TBL] [Abstract][Full Text] [Related]
10. Intake of volatile nitrosamines by Chinese residents in different provinces via food and drinking water.
Li X; Bei E; Qiu Y; Xiao H; Wang J; Lin P; Zhang X; Chen C
Sci Total Environ; 2021 Feb; 754():142121. PubMed ID: 32911156
[TBL] [Abstract][Full Text] [Related]
11. Application of an optimized total N-nitrosamine (TONO) assay to pools: placing N-nitrosodimethylamine (NDMA) determinations into perspective.
Kulshrestha P; McKinstry KC; Fernandez BO; Feelisch M; Mitch WA
Environ Sci Technol; 2010 May; 44(9):3369-75. PubMed ID: 20355696
[TBL] [Abstract][Full Text] [Related]
12. High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans.
Camus AM; Geneste O; Honkakoski P; Béréziat JC; Henderson CJ; Wolf CR; Bartsch H; Lang MA
Mol Carcinog; 1993; 7(4):268-75. PubMed ID: 8352885
[TBL] [Abstract][Full Text] [Related]
13. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome?
Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200484. PubMed ID: 36461687
[TBL] [Abstract][Full Text] [Related]
15. Clearance of N-nitrosodimethylamine and N-nitrosodiethylamine by the perfused rat liver. Relationship to the Km and Vmax for nitrosamine metabolism.
Graves RJ; Swann PF
Biochem Pharmacol; 1993 Mar; 45(5):983-9. PubMed ID: 8461051
[TBL] [Abstract][Full Text] [Related]
16. An Analytical Method for Determining N-Nitrosodimethylamine and N-Nitrosodiethylamine Contamination in Irbesartan, Olmesartan and Metformin by UPLC-APCI-MS/MS in Tablet Dosage Form.
Deeb AA; Hailat M; Aldoqum HM; Abuothman M; Abuyaman O; Abu Dayyih W
J Chromatogr Sci; 2024 Apr; 62(4):372-379. PubMed ID: 37622601
[TBL] [Abstract][Full Text] [Related]
17. Metformin drugs under simulated gastric conditions can generate high nitrite-dependent levels of N-nitrosodimethylamine.
Georgescu GC; Cretu-Stancu M; Bucur O
Sci Rep; 2024 Jun; 14(1):13910. PubMed ID: 38886399
[TBL] [Abstract][Full Text] [Related]
18. Analysis of genotoxic N-nitrosamines in active pharmaceutical ingredients and market authorized products in low abundance by means of liquid chromatography - tandem mass spectrometry.
Vogel M; Norwig J
J Pharm Biomed Anal; 2022 Sep; 219():114910. PubMed ID: 35779354
[TBL] [Abstract][Full Text] [Related]
19. A survey of industrial N-nitrosamine discharges in Switzerland.
Breider F; Gachet Aquillon C; von Gunten U
J Hazard Mater; 2023 May; 450():131094. PubMed ID: 36867906
[TBL] [Abstract][Full Text] [Related]
20. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
